Trial reportScientific reports2025
A prospective multicenter phase III clinical trial evaluating the efficacy and safety of silk elastin sponge in patients with skin defects.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond Early Excision and Grafting: A Perspective on Tissue-Preserving and Regenerative Topical Burn Wound Care.Journal of clinical medicine · 2026Article
- Smart Healing for Wound Repair: Emerging Multifunctional Strategies in Personalized Regenerative Medicine and Their Relevance to Orthopedics.Antibiotics (Basel, Switzerland) · 2026Review
- Design and applications of self-assembled polypeptide matrices in wound healing.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Silk elastin sponge, a novel recombinant protein used for wound healing, has been shown to be effective in promoting macrophage migration, epithelial growth, granulation, and angiogenesis in both preclinical (in vitro and in vivo) and clinical studies. This study aimed to evaluate the efficacy and safety of silk elastin sponges in the treatment of chronic and acute wounds. A prospective multicenter, single-arm, uncontrolled clinical trial included 20 patients with chronic wounds and five with acute wounds, applying the sponge after debridement. The primary endpoints were the percentage of patients with chronic wounds and well-prepared wound beds after 14 days of treatment. The safety of the procedure was also assessed. The results showed that 90.0% of chronic wound patients had well-prepared wound beds by day 14, and 24 out of 25 patients completed the treatment, with one case discontinued due to local infection. This study concluded that silk elastin sponges may be an effective new option for wounds that are unresponsive to existing treatments.Trial registration: jRCT2052210072. Registered on 11 July 2023 in the Japan Registry of Clinical Trials ( http://jrct.niph.go.jp ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.